Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma.
adenocarcinoma
carcinosarcoma
epithelial‐mesenchymal transition
prostate
urethral neoplasms
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
19
06
2020
revised:
11
07
2020
accepted:
14
07
2020
entrez:
9
11
2020
pubmed:
10
11
2020
medline:
10
11
2020
Statut:
epublish
Résumé
Mucinous urethral adenocarcinoma is a rare and progressive cancer of the prostatic urethra. Reports on palliative systemic treatment for mucinous urethral adenocarcinoma are few. We present a case of coexisting mucinous urethral and prostate adenocarcinomas managed with systemic treatment. A 66-year-old man presented with gross hematuria and urinary retention. Prostate-specific antigen level was elevated, at 99 ng/mL, and prostate biopsy revealed moderately to poorly differentiated adenocarcinoma. Hormone therapy and standard chemotherapy for prostate adenocarcinoma were ineffective. Prostate re-biopsy revealed coexisting mucinous urethral and prostate adenocarcinomas. Gemcitabine + cisplatin chemotherapy and folinic acid + 5-fluorouracil + irinotecan chemotherapy temporarily suppressed the cancer, but 14 months after presentation, he developed liver metastasis and died. Autopsy revealed metastasis of both mucinous urethral adenocarcinoma and carcinosarcoma. Mucinous urethral adenocarcinoma is difficult to diagnose in coexistence with prostate adenocarcinoma. This was an extremely rare case showing chemoresistance due to epithelial-mesenchymal transition.
Identifiants
pubmed: 33163919
doi: 10.1002/iju5.12210
pii: IJU512210
pmc: PMC7609175
doi:
Types de publication
Case Reports
Langues
eng
Pagination
261-264Informations de copyright
© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin Imaging. 2020 Jun 16;68:68-70
pubmed: 32574932
Mod Pathol. 2018 Jan;31(S1):S80-S95
pubmed: 29297488
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Am J Surg Pathol. 2007 Sep;31(9):1323-9
pubmed: 17721186
Eur J Cancer. 2012 Mar;48(4):456-64
pubmed: 22119351
Oncology (Williston Park). 2019 Jul 16;33(7):
pubmed: 31365752
Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734
pubmed: 28057415
Cancer. 2012 Dec 15;118(24):6207-16
pubmed: 22674346
Oncotarget. 2017 Apr 4;8(14):22625-22639
pubmed: 28186986
Korean J Intern Med. 2018 Mar;33(2):383-390
pubmed: 27048257